IMUX - Immunic, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Immunic, Inc.

11440 West Bernardo Court
Suite 300
San Diego, CA 92127
United States

http://www.immunic-therapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Daniel VittCEO, Pres & DirectorN/AN/A1968
Dr. Manfred GröppelCo-Founder & COON/AN/AN/A
Dr. Andreas Mühler Ph.D.Co-Founder and Chief Medical OfficerN/AN/A1963
Mr. Sanjay S. PatelChief Financial OfficerN/AN/AN/A
Dr. Hella KohlhofChief Scientific OfficerN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis. The company is also developing IMU-935, an inverse agonist of RORyt; and IMU-856 for the restoration of the intestinal barrier function. Immunic, Inc. is headquartered in San Diego, California.

Corporate Governance

Immunic, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.